Recombinant Human MAGP-2/MFAP5 Protein, CF

Catalog #: 4914-MG Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
4914-MG-050

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human MAGP-2/MFAP5 Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by the ability of the immobilized protein to support the adhesion of BUD‑8 human fibroblast cells. When 2 x 10⁴ cells/well are added to Recombinant Human MAGP-2/MFAP5 coated plates (10 µg/mL with 100 µL/well), approximately 50-75% will adhere after one hour at 37 °C.
Optimal dilutions should be determined by each laboratory for each application.

Source

Mouse myeloma cell line, NS0-derived human MAGP-2/MFAP5 protein
Ile22-Leu173 with a C-terminal 6-His tag

Accession #

Q13361

N-terminal Sequence
Analysis

Ile22 & Ser154

Structure / Form

Monomer

Predicted Molecular Mass

18.1 kDa

SDS-PAGE

25-35 kDa, reducing conditions

Product Datasheets

4914-MG

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

4914-MG

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 400 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: MAGP-2/MFAP5

MAGP-2 (Microfibril-associated glycoprotein 2), also called MFAP5 (microfibril associated protein 5) is a secreted, cell-associated 25 kDa mammalian member of the MFAP family of proteins (1). Human MAGP-2 cDNA encodes 173 amino acids (aa) including a 21 aa signal sequence, an RDG motif (aa 30 ‑ 32; absent in MAGP-1) and a central cysteine‑rich binding domain (aa 84 ‑ 140) (1 ‑ 3). One potential splice variant shows a 10 aa deletion between aa 73 ‑ 82 that includes the only potential glycosylation site (4). Mature human MAGP-2 shares 80%, 82%, 82%, 84% and 85% aa identity with mouse, rat, bovine, porcine and canine MAGP-2, respectively. Both MAGP-1 and MAGP-2 bind and covalently crosslink fibrillins 1 and 2 through the binding domain, but MAGP-2 has more limited distribution and binds a more limited set of extracellular matrix proteins (1 ‑ 3). However, the MAGP-2 RGD motif binds to the integrin alpha v beta 3, allowing cell attachment to microfibrils (5). MAGP‑2 is thought to facilitate microfibril assembly and induce elastin fiber formation (1 ‑ 3, 6). Through its binding to EGF repeats, MAGP-2 mediates the metalloproteinase-dependent release of Jagged1 and the metalloproteinase-independent release of Notch extracellular domains (7, 8). In endothelial cells, MAGP-2 promotes angiogenic sprouting through inhibiting Notch signaling, binding integrin alpha v beta 3 (which then enhances VEGF signaling), and/or enhancing endothelial cell response to FGF basic and EGF (9, 10). In ovarian cancer, MAGP-2 expression is associated with cancer cell survival, increased microvessel density, and poor prognosis (11). Skin MAGP-2 expression is increased in human scleroderma and the tight skin (TSK) mouse; MAGP‑2 may contribute to abnormal collagen accumulation in these conditions by increasing the half-life of type I collagen (12, 13). Fibrillin-1 mutations within the region that binds MAGP-2 can be found in Marfan syndrome (6).

References

Gibson, M.A. et al. (1996) J. Biol. Chem. 271:1096.
Hanssen, E. et al. (2004) J. Biol. Chem. 279:29185.
Segade, F. et al. (2002) J. Biol. Chem. 277:11050.
Genbank protein Accession # AAQ18021.
Gibson, M.A. et al. (1999) J. Biol. Chem. 274:13060.
Lemaire, R. et al. (2007) J. Biol. Chem. 282:800.
Nehring, L.C. et al. (2005) J. Biol. Chem. 280:20349.
Miyamoto, A. et al. (2006) J. Biol. Chem. 281:10089.
Albig, A.R. et al. (2008) Microvasc. Res. 76:7.
Albig, A.R. et al. (2007) Angiogenesis 10:197.
Mok, S.C. et al. (2009) Cancer Cell 16:521.
Lemaire, R. et al. (2005) Arthritis Rheumatol. 52:1812.
Ito, S. et al. (2006) Am.J. Respir. Cell Mol. Biol. 34:688.

Long Name

Microfibril-associated Glycoprotein 2

Entrez Gene IDs

8076 (Human); 50530 (Mouse); 362429 (Rat)

Alternate Names

MAGP2; MAGP-2; MAGP2MFAP-5; MFAP5; Microfibril-associated glycoprotein 2; microfibrillar associated protein 5; microfibrillar-associated protein 5; MP25; MP25microfibril-associated glycoprotein-2